Testicular Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 17320
Special Issue Editor
Special Issue Information
Dear Colleagues,
Testicular Cancer (TC) is the most commonly diagnosed malignant tumor in males between the ages of 16 and 40 years. The incidence of TC continues to rise, and the vast majority of TC patients are diagnosed with clinical stage I disease, either non-seminoma or seminoma testis. The aim of this Special Issue of Cancers is to address the following important clinical knowledge gaps regarding the diagnosis and management of clinical stage I TC: i) the impact of TC diagnosis on psychological and sexual wellbeing and fertility of patients; ii) the need for new and improved detection of prognostic markers to more accurately identify patients at the highest risk of relapse following orchiectomy; iii) controversies surrounding risk-adapted management of adjuvant treatment; and iv) the importance of long-term TC survivorship and monitoring of late side-effects. I sincerely hope this issue of Cancers will be read with great interest by clinicians, researchers, and patients.
Dr. Joost L. Boormans
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- testicular cancer
- clinical stage I disease
- prognosis
- biomarkers
- survivorship
- risk-adapted management
- psychological well-being